Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and ...

Novavax (NASDAQ: NVAX) ended its seventh consecutive session in the red territory after shares of the company declined 1.35% to close at $6.56 on Friday. The vaccine maker lost close to 13% in the ...

In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials ...

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...

As the country continues to deal with the fallout of the infamous Jeffery Epstein files, The Root is taking a closer look at some of the most polarizing conspiracy theories in American history.

WASHINGTON, DC – Dr. Vinay Prasad, the polarizing official who led U.S. vaccine oversight under the Trump administration, has ...

Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.

A fter just a few controversial months, Vinay Prasad, MD, MPH, has stepped down as director of FDA's Center for Biologics Evaluation and Research (CBER).

Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on the ...

After losing 3,500 employees in April—19% of its workforce due to congressional budget cuts—the FDA is now struggling to meet ...